Literature DB >> 20462742

Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents.

Matthew E Falagas1, Evridiki K Vouloumanou, Konstantinos Sgouros, Stavros Athanasiou, George Peppas, Ilias I Siempos.   

Abstract

Clinicians rely on the findings of randomised controlled trials (RCTs) to formulate clinical decisions regarding individual patients. We examined whether patients included in RCTs focusing on antimicrobial agents are representative of those encountered in real-life clinical situations. PubMed was searched for RCTs referring to the field of infectious diseases. Data regarding the exclusion criteria of the identified RCTs were extracted and critically evaluated. In total, 30 trials (17 referring to respiratory tract, 5 to skin and soft-tissue, 4 to intra-abdominal, 2 to gynaecological and 2 to bloodstream infections) were included in the study. All retrieved RCTs reported extensive exclusion criteria. After comparing in a qualitative manner (based on our clinical experience) the eligible patient population in the identified RCTs with the respective population that would be encountered in general practice, it was observed that the abovementioned patient populations differ considerably. In conclusion, RCTs in the field of infectious diseases use extensive and stringent exclusion criteria, a fact that may lead to considerable difference between the patient populations of RCTs and those viewed in clinical practice. The application of the findings of RCTs to the care of individual patients should be performed cautiously. (c) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462742     DOI: 10.1016/j.ijantimicag.2010.03.020

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

Review 1.  Bloodstream infections in older patients.

Authors:  Dafna Yahav; Noa Eliakim-Raz; Leonard Leibovici; Mical Paul
Journal:  Virulence       Date:  2015-12-18       Impact factor: 5.882

2.  Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials.

Authors:  Edward J Schenck; Clara Oromendia; Lisa K Torres; David A Berlin; Augustine M K Choi; Ilias I Siempos
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

3.  Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index.

Authors:  Adrian Gheorghe; Tracy Roberts; Karla Hemming; Melanie Calvert
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

4.  Clinical experience with daptomycin in Europe: the first 2.5 years.

Authors:  Armando Gonzalez-Ruiz; Andres Beiras-Fernandez; Hans Lehmkuhl; R Andrew Seaton; Juergen Loeffler; Ricardo L Chaves
Journal:  J Antimicrob Chemother       Date:  2011-01-25       Impact factor: 5.790

5.  Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials.

Authors:  Matthew E Falagas; Apostolos K A Karagiannis; Theodora Nakouti; Giannoula S Tansarli
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

Review 6.  Clinical drug trials in general practice: how well are external validity issues reported?

Authors:  Anja Maria Brænd; Jørund Straand; Atle Klovning
Journal:  BMC Fam Pract       Date:  2017-12-29       Impact factor: 2.497

7.  Shifting research culture to address the mismatch between where trials recruit and where populations with the most disease live: a qualitative study.

Authors:  Tanvi Rai; Sharon Dixon; Sue Ziebland
Journal:  BMC Med Res Methodol       Date:  2021-04-21       Impact factor: 4.615

8.  Infrastructure challenges to doing health research "where populations with the most disease live" in Covid times-a response to Rai et al. (2021).

Authors:  Jennifer MacLellan; Joanne Turnbull; Catherine Pope
Journal:  BMC Med Res Methodol       Date:  2022-10-08       Impact factor: 4.612

Review 9.  Centre selection for clinical trials and the generalisability of results: a mixed methods study.

Authors:  Adrian Gheorghe; Tracy E Roberts; Jonathan C Ives; Benjamin R Fletcher; Melanie Calvert
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA.

Authors:  Mical Paul; Ella Bronstein; Dafna Yahav; Elad Goldberg; Jihad Bishara; Leonard Leibovici
Journal:  BMJ Open       Date:  2015-09-11       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.